Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Oragenics Inc. (OGEN)
NASDAQ:AMEX Investor Relations:
ir.oragenics.com
Company Research
Source: GlobeNewswire
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that the first patient has been dosed in its ongoing Phase IIa clinical trial evaluating ONP-002, the Company’s lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). The milestone was achieved at Mackay Hospital in Australia — the first site to be activated in the trial — within days of site activation on March 31, 2026. Concussion, aka, mild traumatic brain injury, represents the most prominent neurological conditions without an FDA-approved pharmacological treatment. According to the CDC, an estimated 1.7 to 3.8 million
Show less
Read more
Impact Snapshot
Event Time:
OGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGEN alerts
High impacting Oragenics Inc. news events
Weekly update
A roundup of the hottest topics
OGEN
News
- Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation [Yahoo! Finance]Yahoo! Finance
- Oragenics, Inc. Receives Audit Opinion with Going Concern ExplanationGlobeNewswire
- ORAGENICS FILES ANNUAL REPORT ON FORM 10-K [Yahoo! Finance]Yahoo! Finance
- ORAGENICS FILES ANNUAL REPORT ON FORM 10-KGlobeNewswire
- PRISM BioLab partners with Receptor.AI for molecule discovery [Yahoo! Finance]Yahoo! Finance
OGEN
Sec Filings
- 4/13/26 - Form 8-K
- 3/31/26 - Form 8-K
- 3/23/26 - Form EFFECT
- OGEN's page on the SEC website